Reports

Proposal for the Creation of the National Observatory of Biosimilar Medicines

BioSim (EN) Biosim

Study on the market for biosimilar medicines in the National Health System in Spain

BioSim (EN) Biosim

Report on savings on generic and biosimilar drugs in the US.

Other entities Biosim

“Early Treatment”: The role of biosimilars

BioSim (EN) Biosim

EMA Annual Report 2022

Other entities Biosim

Monograph "Real world evidence: Abstract library"

Other entities Biosim

Biosimilars: innovation from sustainability

BioSim (EN) Biosim

Trends in the field of biosimilars in the United States

Other entities Biosim

Analysis of US Health Savings from Generics and Biosimilars in 2021

Other entities Biosim

Biosimilars in the new National Health System: Proposals for action

BioSim (EN) Biosim

Biosimilars within the new Spanish National Health System. Proposals for action

BioSim Biosim

Public procurement of biosimilar medicines in the National Health System

BioSim (EN) Biosim

Improving Understanding and Acceptance of Biosimilars in the United States

Other entities Biosim

Biosimilars in the treatment of solid tumors

Other entities Biosim

The US Generic & Biosimilar Medicines Savings Report

Other entities Biosim

Biennial Report of BioSim Activities 2019-2020

BioSim (EN) Biosim

Basis for a biosimilar gainsharing project

BioSim (EN) Biosim

Education in Biosimilars - Whitepaper

Other entities Biosim

Clinical management, incentives and biosimilars

BioSim (EN) Biosim

Budget impact analysis of biosimilar medicines in the Spanish National Health System (2009-2022)

BioSim (EN) Biosim

What do we know about biosimilar biologics?

Other entities Biosim

Communication in biosimilar biologics

Other entities Biosim

Variability in the adoption of biosimilars

Other entities Biosim

Hospital expenditure of the National Health System: pharmacy and investment in capital goods

Other entities Biosim

Biosimilars in the United States 2020–2024 COMPETITION, SAVINGS, AND SUSTAINABILITY

Other entities Biosim

Biosimilars, for value-based healthcare

Other entities Biosim

Country Scorecards for Biosimilar Sustainability

Other entities Biosim

Biosimilars in the European Union

Other entities Biosim

The principle of justice and biosimilar medicines in the National Health System (SNS)

BioSim (EN) Biosim

Biosimilars Action Plan: Balancing Innovation and Competition

Other entities Biosim

Biosimilars: new ways to innovate

BioSim (EN) Biosim

What do I need to know about Biosimilar Medicines. Information for patients.

Other entities Biosim

What you should know about biosimilar medicines. European Commission Consensus Report

Other entities Biosim

Proposal for the Creation of the National Observatory of Biosimilar Medicines

Study on the market for biosimilar medicines in the National Health System in Spain

Report on savings on generic and biosimilar drugs in the US.

“Early Treatment”: The role of biosimilars

EMA Annual Report 2022

Monograph "Real world evidence: Abstract library"

Biosimilars: innovation from sustainability

Trends in the field of biosimilars in the United States

Analysis of US Health Savings from Generics and Biosimilars in 2021

Biosimilars in the new National Health System: Proposals for action

Biosimilars within the new Spanish National Health System. Proposals for action

Public procurement of biosimilar medicines in the National Health System

Improving Understanding and Acceptance of Biosimilars in the United States

Biosimilars in the treatment of solid tumors

The US Generic & Biosimilar Medicines Savings Report

Biennial Report of BioSim Activities 2019-2020

Basis for a biosimilar gainsharing project

Education in Biosimilars - Whitepaper

Clinical management, incentives and biosimilars

Budget impact analysis of biosimilar medicines in the Spanish National Health System (2009-2022)

What do we know about biosimilar biologics?

Communication in biosimilar biologics

Variability in the adoption of biosimilars

Hospital expenditure of the National Health System: pharmacy and investment in capital goods

Biosimilars in the United States 2020–2024 COMPETITION, SAVINGS, AND SUSTAINABILITY

Biosimilars, for value-based healthcare

Country Scorecards for Biosimilar Sustainability

Biosimilars in the European Union

The principle of justice and biosimilar medicines in the National Health System (SNS)

Biosimilars Action Plan: Balancing Innovation and Competition

Biosimilars: new ways to innovate

What do I need to know about Biosimilar Medicines. Information for patients.

What you should know about biosimilar medicines. European Commission Consensus Report

ABOUT BIOSIM

ABOUT BIOSIMILARS

BioSim Newsletter